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in specific situations, by the progeny of hematopoietic 
stem cells (HSCs), pointing to a strategy to engineer the 
CNS environment through the transplantation of modified 
HSCs. Thus, microglia replacement has been successfully 
exploited to deliver therapeutics to the CNS in human dis-
eases such as X-ALD and LSD. with this outlook in mind, 
we will discuss the evidence existing so far for microglial 
involvement in the pathogenesis and the therapy of specific 
CNS disease.
An introduction to microglia
Microglia constitute approximately 10 % of the total glial 
cell population within the CNS, with the density of these 
cells varying considerably between different anatomical 
regions, ranging from a high of 12 % in the basal ganglia to 
a low of 5 % in the cortex of mice [83]. Ramon y Cajal ini-
tially identified a population of cells distinct from neurons 
and macroglia (astrocytes); he designated “third element”, 
which was further divided into a main population repre-
senting oligodendrocytes, with the remainder of the cells 
defined as microglia by his student Pio Del Rio-Hortega 
(1919). Using silver carbonate staining of the embryonic 
brain, Rio-Hortega demonstrated that concentrations of 
mesodermal cells from the pia mater, which he referred to 
as “fountains of microglia” appeared on the surface of the 
fetal brain [40]. These cells had an ameboid morphology 
and at later stages of neurodevelopment dispersed through-
out the brain rudiment, and differentiated to into cells with 
the stellate morphology characteristic of microglia.
Despite these early revelations regarding their ontog-
eny, for the better part of a century the identity of the cel-
lular precursor of microglia remained an area of contention, 
with investigations into the origins of microglia generating 
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three different hypotheses. In spite of Rio-Hortega’s early 
assertion that astrocytes and oligodendrocytes were of 
ectodermal origin, while microglia derived from mesoder-
mal precursors, a growing body of evidence supported an 
alternative view that all glial cells derived from a common 
neuro-ectodermal stem cell progenitor, the glioblast [77]. 
In vitro studies reported the development of Mac1+ cells 
in primary astrocyte cultures created by disaggregating the 
murine neonatal cortex and clearing it of microglia by com-
plement-mediated cell lysis, supporting the notion astro-
cytes and microglia originated from a common progeni-
tor [108]. However, when astrocyte progenitors harvested 
from the rat subventricular zone were cultured under media 
conditions favoring microglia differentiation, mixed macro-
glial colonies consisting of astrocytes and oligodendrocytes 
were formed, none of which contained microglia [87].
Alternatively, it was postulated that microglia were 
of hematopoietic origin and were maintained through the 
recruitment of blood-borne monocytes. evidence in sup-
port of their hematopoietic origin came in the form of irra-
diation/bone marrow (BM) transplantation studies in mice, 
in which genetically distinct BM donor cells were observed 
in CNS of recipient mice. However, later experiments dem-
onstrated that in the absence of irradiation [100] and/or the 
intravenous injection of whole BM, which includes progen-
itor populations not found in the circulation under physi-
ological conditions [3], BM-derived cell (BMDC) did not 
infiltrate the CNS. Thus, the accumulation of BMDCs in 
the CNS of chimeric mice was an artifact of the irradiation/
transplantation paradigm used to create BM chimeras, and 
microglia are maintained through local self-renewal rather 
than through the recruitment of monocyte precursors from 
the blood. However, the developmental precursors that give 
rise to microglia were still yet to be identified.
A third hypothesis posited that microglia were the prog-
eny of primitive hematopoietic cells originating in the yolk 
sac (YS) that colonized the brain rudiment during embryo-
genesis. Cuadros et al. [36] employed chimeras between 
chick embryos and quail yolk sacks (YS) to demonstrate 
that macrophages originating from the quail YS invaded 
that developing neuroectoderm of the chick embryo. A sim-
ilar finding was reported by Alliot et al. [5] who showed 
microglia cells first appeared in the brain rudiment of mice 
at day e8.0. Based on this observation, the authors inferred 
that microglial progenitors must have originated in the 
YS, as this was the only site within the mouse embryo that 
contained cells with a macrophage phenotype before e8.0. 
However, at this point in time, the identification of micro-
glial precursors had been muddied with observations made 
using irradiated BM chimeric mice and these studies were 
largely overlooked. It would be over a decade later and fol-
lowing the advent of fate-mapping techniques that the YS 
origin of microglia would be confirmed.
In their seminal work, Ginhoux et al. [51] utilized mice 
expressing a tamoxifen-inducible Cre recombinase under 
the control of a Runx1+ promoter and crossed them with 
the ROSA26-YFP Cre-reporter strain of mice. Runx1 is 
a transcription factor whose expression restricted to YS 
and embryonic liver hematopoietic progenitors. By treat-
ing pregnant females with tamoxifen at different stages 
of embryonic development, YFP would be expressed in 
a proportion (~30 %) of Runx1+ cells and their progeny, 
enabling the migration of YS cells to be mapped within 
the developing embryo. The authors found that when preg-
nant mice were treated with tamoxifen prior to e7.5, a 
time point at which Runx1+ cells are restricted to the YS, 
YFP+ macrophages were observed in the developing brain 
rudiment at e10, e13, and in developed CNS of 6-week-
old mice in a proportion similar to that observed for YS 
macrophages. Notably, when pregnant mice were treated 
with tamoxifen at day e8.5, a time point at which defini-
tive hematopoiesis within the embryo proper has mostly 
replaced YS hematopoiesis, Runx1 lineage traced cells 
were no longer observed in the CNS, indicating that micro-
glia are the progeny of primitive macrophages from the YS 
that invade the developing CNS.
A limitation associated with the study by Ginhoux et al. 
related to the low efficiency (30 %) of Cre recombination 
was addressed in subsequent work by Schulz et al. in 2012 
[135]. They utilized mice in which either the transcrip-
tion factor Myb, required for the development of defini-
tive hematopoiesis but not for myelopoiesis within the 
YS, or Sfpi1, required for development of macrophages, 
was deleted. They showed that the deletion of Myb did not 
affect the development of microglia, while the deletion of 
Sfpi1 resulted in the absence of all macrophages within the 
embryo, including microglia. Thus, in the absence of defin-
itive hematopoiesis in the embryo, microglial development 
is not affected and primitive macrophages originating in the 
YS give rise to microglia. In 2013, Kierdorf et al. [76] iden-
tified the CD45-c-kit+ population of cells within the YS as 
noncommitted erythromyeloid progenitors of primitive YS 
macrophages and microglia.
Under resting conditions, microglia are dynamic cells 
that survey their surrounding microenvironment through 
the projection and retraction of their highly motile pro-
cesses [110]. Detection of homeostatic imbalances, injury, 
or pathology within the CNS elicits a stereotypical pattern 
of activation. In their quiescent state, microglia express 
only low levels of CD45 and MHC proteins; however, 
upon activation the expression of these proteins is robustly 
upregulated [56], with a subpopulation of cells often 
observed to express CD11c [26, 55]. Along with these 
changes in surface phenotype, microglia undergo signifi-
cant morphological changes, characterized by the retraction 
and thickening of their ramified processes and cell body 
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hypertrophy [78]. Under conditions of neurodegeneration, 
populations of microglia acquire an ameboid morphology 
that is associated with increased phagocytosis, and serve to 
clear degenerative debris [58]. However, these surface phe-
notype and morphological changes are not an indication of 
the inflammatory gene repertoire expressed by these cells.
The CNS has several unique immunological features 
that together constitute immune specialization in compari-
son to other tissue compartments. The endothelium of the 
blood–brain barrier (BBB) strictly regulates the transmis-
sion of blood-borne substances and cells into the CNS, cre-
ating a sterile environment. Microglia exhibit a quiescent 
phenotype compared to other populations of tissue mac-
rophages [92] and the CNS lacks an extensive lymphatic 
drainage system. The interplay between different cell types 
also contributes to maintaining this subdued immunologi-
cal milieu. Neurons play an integral role in maintaining 
the quiescent state of microglia through the expression of 
membrane-bound ligands such as CD200 and CX3CL1, 
which function through cognate receptors expressed on the 
surface of microglia to down-regulate inflammatory gene 
expression [28, 63]. This immune specialization within the 
CNS serves to suppress and strictly regulate inflammatory 
responses that can damage surrounding neurons, which 
have only limited regenerative capabilities. Thus, in vitro 
studies of microglial activation must be interpreted with 
caution, as the phenotype of these cells is highly dependent 
on the specialized microenvironment within the CNS.
As will be discussed further, in the context of neurologi-
cal diseases, microglia can promote neuronal survival or 
exacerbate the disease process depending on their activa-
tion profile, and are thus key players in influencing disease 
progression.
Microglia in amyotrophic lateral sclerosis (ALS)
ALS is a fatal neurodegenerative disease characterized by 
the progressive loss of both upper (brain) and lower (brain 
stem and spinal cord) motoneurons, culminating in advanc-
ing paralysis. A variety of genetic mutations cause familial 
ALS, with a proportion (20 %) of these cases due to muta-
tions in superoxide dismutase 1 (SOD1) [13]. Transgenic 
mice that over-express mutant SOD1 (mSOD) develop pro-
gressive motoneuron degeneration that is similar to ALS 
[57]. However, deleting the orthologous SOD1 in mice 
does not cause neurodegeneration, indicating that mSOD 
neurotoxicity operates through a gain of function mecha-
nism [125, 136]. As with the vast majority of neurological 
diseases, neuropathology in ALS and the mSOD model is 
accompanied by robust microglial activation, and whether 
microglial activation has a correlative or causative role in 
neurodegeneration has been hotly debated [67].
Substantial experimental evidence has implicated micro-
glial activation as a contributing factor to neurodegenera-
tion in the mSOD model. In vitro studies have demonstrated 
that mSOD-expressing microglia stimulated with LPS pro-
duced greater amounts of pro-inflammatory factors includ-
ing NO, superoxide, IL-6 and TNFα, and reduced levels of 
IGF-1 compared to similarly treated wild-type microglia 
[156, 161]. when microglia were co-cultured with moto-
neurons following activation by LPS, the increased produc-
tion of NO and superoxide by mSOD microglia resulted in 
enhanced neurotoxicity compared to wild-type microglia 
[161]. However, removing microglia from the environment 
of the CNS significantly alters their behavior and due to the 
BBB, bacterial antigens such as LPS would not typically be 
encountered in the intact CNS.
To determine whether microglial dysfunction caused by 
mSOD expression contributes to causing neurodegeneration 
in vivo, Boillee et al. [24] utilized mice carrying a floxed-
mSOD transgene crossed to strains expressing Cre recom-
binase to ablate mSOD expression in neurons or microglia. 
while investigators found that neuronal mSOD expres-
sion was required for the onset and early stages of dis-
ease, blocking mSOD expression in microglia significantly 
delayed the progression of disease and extended lifespan. 
Similarly, when the microglial compartment of mSOD mice 
was reconstituted with wild-type microglia, disease pro-
gression was slowed and survival was extended [16]. while 
investigators postulated these observations were due to the 
enhanced neurotoxicity of mSOD microglia compared to 
wild type, which had been demonstrated in vitro, an alterna-
tive explanation could be that mSOD expression in micro-
glia reduces their neurotrophic potential.
Although these studies vilified microglia as drivers of 
neurodegeneration in the mSOD model, subsequent work 
casts doubt on their neurotoxicity. when proliferating 
CD11b+ microglia were selectively ablated in the CNS of 
mSOD mice, resulting in over a 50 % reduction in the num-
ber of activated microglia in the lumbar spinal cord, no effect 
was observed on disease progression [55], and gene expres-
sion profiling of spinal cord microglia from mSOD mice 
revealed that microglia maintain a primarily neuro-support-
ive phenotype throughout the course of disease [33].
Interestingly, the phenotype of microglia in mSOD 
mice evolved with disease progression, with cells exhib-
iting an neurotrophic phenotype at disease onset and a 
potentially neurotoxic phenotype by disease end-stage 
[89]. More recently, deep RNA sequencing of mSOD 
spinal cord microglia revealed that microglia co-express 
neurotrophic (e.g., IGF1, progranulin) and neurotoxic 
factors [34]. Thus microglia are primed to either delay or 
exacerbate neurodegeneration depending on the balance 
between the production of trophic versus toxic factors. 
Tipping this balance in favor of a neurotrophic phenotype 
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may be a site for therapeutic intervention. Indeed, Neural-
tus Pharmaceuticals is currently testing the efficacy of its 
drug NP001 in delaying the progression of ALS. Rather 
than universally dampening microglial responses, NP001 
functions to skew microglial activation toward an M2 
phenotype, enhancing the production of neurotrophic fac-
tors while down-regulating the production of neurotoxic 
substances. Phase 2 results demonstrated that in the high-
dose patient group, there was no progression of disease in 
27 % of patients treated, a 2.5-fold improvement over the 
placebo group (Neuraltus Pharmaceuticals Oct.29, 2012 
release).
Microglia in Alzheimer’s disease (AD)
AD is characterized by the degeneration of synapses and 
neurons, culminating in altered cognitive functions. The 
pathological hallmarks within the AD brain are senile 
plaques formed by the extracellular deposition and accu-
mulation of beta amyloid (Aβ), and intraneuronal neurofi-
brillary tangles of hyperphosphorylated tau filaments [106].
The cause of neurodegeneration in AD has yet to be elu-
cidated, though several pathogenic mechanisms have been 
postulated, including mitochondrial dysfunction and the 
accumulation of Aβ. Aβ is a peptide produced by the cleav-
age of amyloid precursor protein (APP), an integral mem-
brane protein expressed by a multitude of cells but found in 
high concentrations at neuronal synapses, though the func-
tion of APP remains unknown.
As with many other neurodegenerative diseases, whether 
the inflammatory response associated with AD serves to 
drive or delay disease progression is a contentious and 
complex issue. Microglia are observed to cluster around Aβ 
deposits in AD brain and constitute a cellular component of 
senile plaques [97]. Notably, Aβ directly activates the clas-
sical complement pathway by interacting with C1q protein, 
triggering a complement cascade that results in the opsoni-
zation of plaques [129]. As microglia express scavenger 
receptors for opsonized targets, they are in turn activated 
and migrate toward senile plaques. Indeed, numerous scav-
enger receptors expressed by microglia have been shown to 
interact with Aβ including CD36 [75], class A1 scavenger 
receptors (Scara1) [74], and the receptor for advanced gly-
cation end products (RAGe) [164], to name a few. Indeed, 
Frenkel et al. [50] demonstrated that ablating expression 
of Scara1, resulted in increased levels of Aβ deposition, 
while the pharmacological up-regulation of this receptor 
increased Aβ clearance.
In vitro studies showed that microglia stimulated with 
Aβ produced factors toxic to co-cultured neurons, while 
treating neuronal cultures with Aβ in the absence of micro-
glia did not result in neuronal death [52]. while these 
results suggest that microglial activation in AD might serve 
to enhance neurotoxicity, later in vivo studies suggested 
otherwise. Overexpression of IL-1B in the brains of AD 
mice resulted in increased levels of microglial activation 
with a concomitant reduction of Aβ deposition in the hip-
pocampus [138]. A protective function for microglial acti-
vation was further supported by the recent discovery that a 
variant in the gene encoding triggering receptor expressed 
on myeloid cells 2 (TReM2) increases the risk develop-
ing sporadic AD threefold [68]. TReM2 is expressed on 
the surface of myeloid cells, including dendritic cells, 
macrophages and is constitutively expressed by microglia. 
Loss-of-function mutations in the gene encoding TReM2 
or the adaptor protein through which it signals (DAP12) 
results in Nasu-Hakola disease, characterized by bone cysts 
and progressive encephalopathy and neurodegeneration 
that culminates in cortical atrophy and early-onset demen-
tia [109]. Takahashi et al. [152] demonstrated that ablating 
TReM2 expression in microglia inhibits their phagocyto-
sis and elimination of apoptotic neurons and increases their 
production of TNFα and NOS2. Thus it has been hypoth-
esized that in the context of AD, TReM2 genetic variants 
serve to reduce the ability of microglia to phagocytize Aβ 
and enhance their expression of pro-inflammatory factors, 
resulting in accelerated accumulation of Aβ and neurotox-
icity [61].
Recently, microglial senescence has been postulated to 
play a role in the development of AD. with increasing age, 
the number of microglia in numerous areas of the murine 
CNS significantly increases, their cortical distribution 
becomes less organized and uneven [158], and microglial 
processes exhibit reduced branching and symmetry [153]. 
In the aged human brain, microglia possess an activated 
morphology [101], with some cells appearing dystrophic 
[149]. Functionally, aged microglia express increased lev-
els of pro-inflammatory cytokines (e.g., TNFα, IL-1B) 
and reduced anti-inflammatory IL-10 expression [158]. 
Together, these changes suggest aged microglia are in a 
heightened state of basal of activation compared to their 
younger counterparts, suggesting that they would be more 
efficient at responding to and at removing accumulating 
Aβ. However, in vitro studies of microglia from the brains 
of aged AD mouse models demonstrated that despite 
the heightened activation of these cells, the expression 
of scavenger receptors that bind Aβ and Aβ-degrading 
enzymes, such as neprilysin and insulysin, is actually 
reduced [60]. Furthermore, an in vitro study comparing 
the ability of young and aged murine microglia demon-
strated that aged cells take-up comparatively reduced lev-
els of Aβ [111]. Thus a model has been suggested where 
microglia initially serve protective functions in the AD 
brain by phagocytizing Aβ; however, despite the increased 
accumulation of microglia with disease progression in 
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brain, age-related microglia dysfunction reduces the 
clearance of Aβ, while the production of pro-inflamma-
tory cytokines is increased [60]. Compounding this dys-
function is the observation that inflammatory cytokines 
(e.g., IFNγ, TNFα) serve to enhance the activity of both 
γ-secretase [90] and β-secretase, increasing the produc-
tion of Aβ and the formation of senile plaques [163], and 
eventually creating a self-perpetuating cycle of inflamma-
tion and Aβ deposition.
Microglia in Huntington disease
Huntington disease is caused by the expansion of a trinu-
cleotide repeat within the Huntingtin (HTT) gene, leading 
to the formation of an extended polyglutamine stretch at the 
N-terminal of the protein Huntingtonin [130]. This leads to 
a progressive degenerative disease associated with loss of 
medium spiny GABAergic neurons in the striatum. while 
it has been widely thought that the mechanism underlying 
HD pathology is likely cell autonomous and dependent of 
neuronal expression of the protein, microglia activation 
takes place prior to the onset of overt symptoms, its accu-
mulation in the brains of Huntington patients takes place 
early during disease progression [132] and correlates with 
disease severity [117]. This suggested that the involvement 
of the inflammatory system may be tightly linked to the 
underlying pathogenesis rather than simply being one of its 
outcomes [151]. Surprisingly, further analysis found that 
mutant HTT (mHTT) is capable of affecting the inflamma-
tory system in a systemic fashion. An increase in inflam-
matory cytokines such as IL-6, IL-8 and TNFα was found 
first in the plasma of overt Huntington’s patients, and later 
in that of pre-symptomatic mutation carriers [37]. Further 
investigation in murine models carrying HTT transgenes 
including expanded repeats pointed to the fact that periph-
eral monocytes as well as alveolar macrophages, neither 
of which are thought to traffic through the CNS in homeo-
static conditions [3], showed increased cytokine production 
in response to in vitro LPS stimulation [23].
A strong indication that cell autonomous effects are 
indeed at the basis of microglia hyper-excitability has 
been provided by the finding that expression of a mHTT 
transgene specifically in myelomonocytic cells is sufficient 
to induce such phenotype [35]. Surprisingly, however, and 
in contrast with previous literature, in this study, no effects 
of mHTT expression were seen on peripheral myelomono-
cytic cells. In addition, whether mice expressing mHTT 
specifically in microglia actually developed a disease 
mimicking Huntington was not reported, leaving the ques-
tion of the pathogenic relevance of the observed changes 
open. Thus, while it is clear that microglia is altered in a 
cell autonomous way by expression of HTT containing 
expanded repeats, the relevance and mechanistic underpin-
ning of such changes are not yet clear.
Microglia in multiple sclerosis/experimental 
autoimmune encephalomyelitis
Multiple sclerosis is a chronic inflammatory disease with 
a significant autoimmune component that leads to demy-
elination and eventually progressive loss of functional 
neurons. Typically two phases of the disease can be recog-
nized based on symptom progression: a relapsing–remit-
ting phase in which damage is invariably associated with 
inflammatory infiltrates and a second “progressive” phase 
in which functional loss continues at a steady pace, some-
times without any signs of inflammation. Active lesions 
are always associated with the presence of activated mac-
rophages and/or microglia [82], which has led to the wide-
spread belief that these cells play an active role in MS 
pathogenesis. whether such role entails causing damage or 
actually limiting it, or perhaps both at different stages of 
the disease, has been debated [67].
The most commonly used murine model of MS relies 
on the induction of autoimmunity by immunization of 
mice with specific myelin peptides and complete Freund’s 
adjuvant. There are several caveats with this model, and 
for the purposes of this review a main limitation is the fact 
that the nature of the inflammatory infiltrate observed in 
active lesions is significantly different from that observed 
in human samples. CD4T cells, rather than CD8, predomi-
nate and B cells are nearly absent. This last difference in 
particular is critical when considering the recent successes 
of specific anti-B cell therapies, which lead to a dramatic 
amelioration of MS-linked inflammation and can prevent 
acute relapses, even if they are eventually unable to arrest 
the disease progression [85]. Yet despite these caveats, it 
is from these experimental autoimmune encephalomyelitis 
(eAe) models that evidence for distinct roles of resident 
microglia and infiltrating cells arises.
One of the problems limiting our ability to gain a deeper 
understanding of the specific roles of microglia is the fact 
that despite a number of candidates having recently been 
proposed, we still lack a reliable marker to distinguish 
these cells from BM-derived macrophages. This distinction 
is particularly important in MS, as macrophages derived 
from infiltrating monocytes and microglia are both present 
in the CNS parenchyma [4].
Over the past few years, murine models have been 
developed that have led to significant progress. A model 
based on irradiation of parabiotic animals was developed 
in which circulating and resident cells can be easily dis-
tinguished. Using this model a temporal sequence was 
revealed in which massive microgliosis takes place before 
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the development of severe symptoms and the concomitant 
infiltration of circulating cells. Indeed studies taking advan-
tage of the fact that deleting the chemokine receptor CCR2 
blocks the ability of monocytes to enter the CNS confirmed 
that their infiltration is an absolute requirement for the 
development of severe disease [4, 99].
The observation that microglial activation occurs early 
during disease suggested that while it may not be responsi-
ble for the majority of inflammatory damage, it might initi-
ate a cascade of events eventually leading to the entry of 
deleterious inflammatory monocytes into the CNS. Another 
early event that has been linked to microglia activation is 
the disruption of the blood–brain barrier (Fig. 1a, b). The 
development of localized vascular permeability has been 
proposed to play a key role in microglia activation through 
the extravasation of serum components such as comple-
ment [124]. One of the most abundant serum components 
is fibrinogen. Beyond its well-studied role in coagulation, 
fibrinogen is also known to have powerful pro-inflamma-
tory effects, partly by providing an adhesion substrate for 
CD11b, an integrin expressed on most myelomonocytic 
cells. Fibrinogen depletion has also been shown to reduce 
the severity of eAe, and this effect has been attributed to 
interference with its role in activating resident microglial 
cells [2]. More recently, fibrinogen extravasation has been 
linked to the formation of microglial perivascular clusters 
beginning in pre-symptomatic eAe and lasting through to 
peak of disease, and the presence of such clusters has been 
linked to disease progression [38]. However, fibrinogen 
depletion-mediated disruption of microglial clusters still 
allows eAe to proceed to mild symptomatic stages, which 
include microgliosis. This suggests that fibrinogen may 
have multiple roles, and that while it may not absolutely 
required for microglial activation it may influence mono-
cytic infiltration and thus disease progression.
while the progeny of inflammatory monocytes is gener-
ally recognized as a key effector of demyelination in both 
autoimmune and other pathologies, a role for microglia 
Fig. 1  Illustration of the multiple roles of microglia during the ini-
tiation, progression and resolution of experimental autoimmune 
encephalitis. The spinal cord sections are derived from mice in which 
circulating cells and their progeny are marked by GFP expression 
(green), while tissue-resident microglia are not (see text). a Micro-
scopic leaks in the CNS vasculature allow the extravasation of plasma 
components such as fibrinogen, which contributes to the induction 
of microglia expansion. b This leads to microgliosis well before cir-
culating cells are capable of crossing the blood–brain barrier. Stain-
ing for the mature microglia/macrophage marker IBA-1 is shown 
in red, staining for CD31 (endothelium) in blue, circulating cells 
are green. c expanded microglia play a role in attracting circulating 
inflammatory monocytes, possibly by the expression of chemokines 
such as CCL2/MCP1. d Inflammatory monocytes infiltrate the CNS 
parenchyma and, through a variety of mechanisms likely to involve 
myelin stripping and secretion of neurotoxic cytokines, exacerbate 
the damage and trigger progression toward severe disease. e, f Next, 
inflammatory monocytes mature into IBA-1 expressing macrophages, 
adopting a microglia-like morphology. This signals the beginning 
of remission. g eventually, macrophages derived from circulating 
monocytes are completely cleared from the CNS, while microglia is 
reduced in numbers but persists to maintain the resident population of 
innate immune cells
▸
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in the pathogenesis of eAe has also been established. In 
a seminal paper in which microglia expansion had been 
prevented, mice failed to progress to severe disease upon 
eAe induction [59]. More recently, a revolutionary trans-
genic strategy allowing specific genetic manipulation of 
microglia and not of BM-derived cells has led to the clear-
est evidence so far that microglia are indeed involved in 
eAe pathogenesis. This strategy takes advantage of the 
fact that microglia self-renews in situ without involvement 
of BM cells, while short–lived circulating myelomonocytic 
cells are continuously replaced. Thus the lasting deletion of 
specific genes only in microglia can be obtained by tran-
siently inducing CRe activity in myelomonocytic cells, and 
then waiting for the peripheral cells to be replaced by the 
progeny of undeleted stem cells. This strategy, which is sig-
nificantly simpler than the parabiosis/irradiation approach 
mentioned above, allowed Goldmann et al. [54] to delete 
the signal transducer TAK1, involved in the activation of 
stress and of pro-inflammatory pathways through NF-kB, 
specifically from microglia. when these animals were sub-
jected to eAe induction, they were found to be resistant to 
disease despite the fact that appropriate T cell responses 
were normally established in the periphery. In addition, the 
observation that cells lacking TAK1 lost the ability to acti-
vate CCL2 expression led the authors to hypothesize that 
one of the roles of microglia may be to attract inflamma-
tory monocytes (Fig. 1c, d).
Another proposed role for microglia in eAe pathogen-
esis relates to antigen presentation. In MS, like in eAe, 
the repertoire of self-antigens against which T cells are 
capable of reacting increases during disease progression, 
and such “epitope spreading” is likely to play a significant 
role in exacerbating demyelination [84]. epitope spread-
ing has been shown to start from within the CNS rather 
than in peripheral lymphoid organs, suggesting that cells 
capable of presenting antigen and activating novel T cell 
clones must be present locally [98]. For efficient antigen-
specific activation of T cells, an antigen-presenting cell 
(APC) expressing both antigen-loaded MHC and co-stimu-
latory molecules is required. while quiescent microglia do 
not express significant levels of these molecules at steady 
state, both MHC-I and MCH-II are upregulated in activated 
microglia, which also express co-stimulatory molecules 
such as CD40 and CD80/86 [71, 133]. when the ability of 
microglia to stimulate T cells was assessed in models of 
cuprizone-induced demyelination, it was found that they 
increased expression of MHC, the putative APC marker 
CD11c and co-stimulatory molecules as mentioned above, 
and that they were capable of efficiently presenting myelin 
peptides to T cell in vitro [126]. However, no evidence of T 
cell activation in vivo was found, pointing out limitations 
of assays that probe the ability of a given cell type to pre-
sent antigen outside of its physiological context.
Finally, microglia have also been ascribed positive 
roles in eAe. These roles are mostly related to their abil-
ity to polarize to an alternatively activated, “M2” like state 
in response to type-2 cytokines, and to remove inhibitory 
myelin debris interfering with remyelination (Fig. 1e, f). 
Treatment of microglia with IL-4, a typical type-2 polar-
izing factor, reduces expression of pro-inflammatory genes 
such as TNFα and increases the expression of trophic fac-
tors capable of stimulating oligodendrocyte precursors such 
as IGFs. Delivery of IL-4 treated cells in the cerebrospinal 
fluid of mice led to a faster resolution of eAe [25]. In addi-
tion, microglia themselves express IL-4 upon activation, 
suggesting that it may play a role in inducing the M1 to M2 
switch that the progeny of infiltrating monocytes undergoes 
just prior to eAe remission [4]. In support of a critical pos-
itive role of IL-4 in the CNS, mice lacking IL-4 or IL4Rα 
display exacerbated eAe [47], and this phenotype was not 
rescued by transplantation of wild-type BM in IL-4−/− 
recipients, suggesting that resident radioresistant cells such 
as microglia are the critical source of this cytokine [120]. 
Interestingly, in this setting, both microglia and infiltrat-
ing cells lost expression of the M2 marker Ym1 support-
ing the notions that IL-4 may influence microglial fate in an 
autocrine fashion and that microglia-derived cytokines may 
modulate infiltrating cell fate.
Microglia in X‑ALD
X-linked adrenoleukodystrophy (X-ALD) is a meta-
bolic genetic disease with a frequency of 1:17.000 males 
that causes progressive inflammatory demyelination in 
the brain. X-ALD results from mutations in the ABCD1 
gene located in the chromosome Xq28. The ALD protein 
is a member of the adenosine triphosphate-binding cas-
sette (ABC) transporter family [104, 105] expressed in 
the peroxisomal membrane. ALD protein loss of function 
results in the accumulation of unbranched saturated very-
long-chain fatty acids (vLCFAs) in body fluids and tissues 
particularly brain and adrenal cortex [62, 66, 102]. Several 
distinct phenotypes occur frequently within the same fam-
ily and are not correlated with ABCD1 gene mutations. 
The most prevalent form of X-ALD is a slowly progres-
sive paraparesis with sphincter disturbances referred to 
as adrenomyeloneuropathy (AMN). AMN affects adult 
males after the age of 20 years and frequently heterozy-
gous women after the age of 40 years. AMN is due to the 
involvement of the long tracts in the spinal cord leading to 
axonal degeneration. The cerebral form of X-ALD mani-
fests in childhood as an acute cerebral demyelinating dis-
ease with neuroinflammation. The affected boys develop 
normally until 4–12, then cerebral demyelinating lesions 
start in the corpus callosum, internal capsules or brain stem 
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and progress initially slowly over 1–3 years with mild neu-
rocognitive deficits and no neurologic abnormalities. After 
this initial period, rapid cerebral demyelination occurs 
with a devastating clinical course. At this stage, brain MRI 
shows marked progression of demyelination and focal dis-
ruption of the blood–brain barrier. This rapid aggravation 
corresponds to the onset of inflammatory lesions, with 
infiltration and accumulation of macrophages and mononu-
clear cells behind the active edge of demyelinating lesions 
[44]. Most patients enter a vegetative state within 2–4 years 
of the first symptoms followed at varying intervals there-
after by death in 90 % of the cases. whereas heterozygous 
women with AMN never develop the cerebral form (unless 
they have ABCD1 gene mutation on both alleles), 35 % of 
AMN males develop a cerebral demyelinating form of the 
disease between 20 and 35 years of age with the same out-
come as in young boys toward vegetative state or death few 
years after the onset of neurologic symptoms.
The initiation of cerebral demyelination could be 
directly linked to the amount of vLCFA in complex lipids, 
such as phosphatidylcholines, sulfatides or gangliosides 
and to the inefficient degradation of vLCFA. This accumu-
lation of vLCFA in myelin could lead to progressive desta-
bilization of myelin sheaths and demyelination [62, 103]. 
Then this initial cerebral demyelination converts into a rap-
idly progressive inflammatory demyelination with invasion 
of macrophages containing myelin degradation products 
and opening of the blood–brain barrier [103].
Neuropathological analysis from ALD brains allowed 
major insight into the evaluation of the role of microglia 
in ALD [44]. Perivascular macrophages were shown to 
closely follow the leading edge of the demyelinating lesion. 
The region in which perivascular macrophages accumulate 
shows breakdown of the blood–brain barrier and accumu-
lation of contrast material on gadolinium-enhanced mag-
netic resonance imaging (MRI). These blood-derived mac-
rophages play a crucial role in the removal of myelin debris 
as revealed by the presence of recently degraded myelin 
lipids within them. Unexpectedly a zone lacking micro-
glia within myelinated white matter was found beyond 
the leading edge. Given the spatial and temporal evolu-
tion of lesions in X-ALD, this loss of microglia could pre-
cede demyelination. Interestingly, the edge of the regions 
where microglia were absent showed activated microglia. 
This pattern of microglial activation is intriguing and offers 
clues to the pathogenesis of demyelination [44]. This area 
of activation is only seen in perilesional myelin, not in 
unaffected regions of the brain, and corresponds to areas 
where myelin contains higher levels of vLCFAs. Microglia 
in this region could be unable to degrade vLCFAs, and the 
cytotoxicity of lyso-phosphatidylcholine (LPC) contain-
ing vLCFA for macrophages and microglia could in turn 
lead to microglial activation and apoptosis [18, 44]. This 
microglial dysfunction and apoptosis might constitute an 
early pathogenic change in cerebral X-ALD, contributing 
to neuroinflammation and altering the neurovascular unit. 
elevated levels of pro-inflammatory chemokines (CCL2, 
CCL4, IL-1ra, CXCL8) have been observed in the cerebro-
spinal fluid of patients with cerebral X-ALD and correlate 
with the MRI severity [93].
Altogether this suggests that, as observed in other neu-
rodegenerative diseases like ALS, the process of demyeli-
nation in cerebral X-ALD might not be cell autonomous. 
Although the oligodendrocyte and the axon are the evi-
dent targets in cerebral X-ALD, the loss of microglia and/
or abnormal microglia function could impair the ability to 
provide neuroprotective factors to deficient oligodendro-
cytes [53]. Injury to oligodendrocytes might be enhanced 
via an inflammatory response that follows tissue injury and 
plays an important role by initiating and accelerating the 
progression of the disease [53].
Microglia dysfunction in Rett syndrome
Rett syndrome (RTT) is an X-linked CNS developmental 
disorder primarily affecting girls linked to loss-of-func-
tion mutations in the X-linked MeCP2 gene encoding 
methyl-CpG-binding protein 2 [7, 31, 141]. RTT combines 
neuronal damage to non-cell-autonomous glial dysfunc-
tion. Neurons are primarily affected in the disease with 
dendritic and synaptic abnormalities [9, 112] and stud-
ies have initially supported an exclusively neuronal role 
for Mecp2 in RTT pathology. However, neuron-restricted 
expression of Mecp2 protein is insufficient to fully rescue 
the disease phenotype and glial cells were also shown to 
play a major role in the physiopathology of the disease [6, 
12, 95]. expression of Mecp2 in astrocytes was shown to 
arrest disease progression in Mecp2-null mice [91] and 
the toxicity of Mecp2-null microglia to neurons was sug-
gested. Microglia was shown to release an abnormally high 
level of glutamate, causing excitotoxicity [94]. The role of 
microglia in RTT was addressed using BM transplantation 
Mecp2-null male mice. Surprisingly, pathology was halted 
and survival strongly increased (from 8 weeks to nearly 
1 year) and animals showed remarkable improvement in 
several characteristic disease phenotypes including apnea, 
tremors, and locomotor performance. Myeloablative con-
ditioning of the brain itself had no beneficial effect. Since 
major impairment in phagocytic ability of primary Mecp2-
null microglia was evidenced in vitro, it was suggested that 
insufficient clearance of debris within the brains of these 
animals could contribute to the severity of the pathol-
ogy and that phagocytic clearance by microglia could be 
important to improve the disease [41, 42]. Microglia could 
induce neuronal injury then subsequently fail to remove 
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properly neuronal debris. This impaired phagocytic activ-
ity of microglia may not only contribute to RTT, but more 
largely to the pathophysiology of other CNS disorders. 
This is suggested by the observation that TReM2 myeloid 
cell receptor dysfunction is implicated in Nasu-Hakola 
disease, a pathological condition that shares similar phe-
notypic abnormalities with RTT [116]. TReM2 signaling 
was shown to facilitate debris clearance by microglia [152]. 
These data have strong implications for the treatment of 
RTT. A more detailed description of the role of microglia in 
RTT is available in this issue.
Microglia replacement as a therapeutic tool for CNS 
diseases
Turn over of brain microglia after hematopoietic cell 
transplantation (HCT)
Substantial debate remains on the existence, the modali-
ties, and the kinetics of CNS microglia replacement by 
hematopoietic-derived cells after HCT [3, 100]. Many in 
vivo studies suggest that microglia are maintained after 
birth by local precursors that colonize the brain before 
birth independently from circulating mononuclear cells 
[3, 51, 100, 122, 142]. However, studies in irradiated mice 
demonstrate that an increased microglial engraftment of 
BM cells is observed after brain lesions suggesting that 
recruitment of BM-derived microglia (BMDM) occurs 
in many types of neuroinflammatory, neuroinfectious or 
neurodegenerative processes with or without alteration 
of the blood–brain barrier [39]. Thus neuroinflammation 
and microglia activation could promote recruitment of 
BM-derived cells to the CNS [119, 131]. Multiple exam-
ples comprise not only stroke [122] neurodegenerative 
diseases like Alzheimer’s disease [143], ALS [16, 70, 88, 
146], Parkinson’s disease [128], multiple sclerosis [49] 
leukodystrophies [159] but also focal neuronal degenera-
tion, traumatic brain injury [144] or experimental neuro-
pathic pain. These BMDM are clearly distinct from CNS-
infiltrating terminally differentiated macrophages [16, 
122, 143, 157].
experiments performed in myeloablated mice recon-
stituted with green fluorescent protein (GFP+) BM cells 
showed that both perivascular macrophages and microglia 
were replaced, to some extent, by BM-derived cells [10, 43, 
122, 142, 159]. These studies showed progressive recon-
stitution of a significant fraction of differentiated, resting 
microglia a few months after HCT. However, the turn over 
of brain microglia after HCT is a slow process. Indeed, 
3 months after reconstitution, the engraftment rate of Iba1 
positive donor-derived microglia was estimated to reach 
25 % 12 months after transplantation [30, 121].
Microglia depletion as a tool to create a monocyte/
microglia niche in the CNS
Busulfan conditioning regimen was recently shown to 
allow efficient turnover of microglia with donor-derived 
elements by modulating the local brain environment, likely 
by creating “space” for the engraftment through deple-
tion of endogenous microglia [19, 88]. These experiments 
mimic the concept of myeloablation used in HCT proce-
dures. The identification of donor-derived cells proliferat-
ing in the brain long-term after HCT and the appearance 
of progressively more mature donor cells [10], suggest that 
following myeloablation (albeit not in physiologic condi-
tions) myelomonocytic reconstitution of the CNS can result 
from expansion and maturation of donor-derived precursor 
cells that are able to migrate in the brain short-term after 
HCT and proliferate locally. This is an important finding 
that could explain the efficacy of hematopoietic stem cell 
(HSC) gene therapy observed in X-ALD. In this trial, com-
parable efficacy of gene therapy to that described in ALD 
subjects showing full donor chimerism after allogeneic 
HCT was observed despite a limited engraftment in the BM 
and a number of corrected circulating mononuclear cells 
below 15 % [30]. HSCs might be required for obtaining 
microglia replacement by the donor because they comprise 
a cell subpopulation able to replace the intraparenchymal 
microglia precursors that are eliminated upon myeloabla-
tive conditioning, rather than because they ensure long-
term hematopoietic donor engraftment in the BM [3, 19].
Using monocytes to potentially replace dysfunctional 
microglia
Supporting the view that mature monocytes are a potential 
source of BMDM, several in vitro studies demonstrated 
that murine or human mature monocytes differentiate into 
microglia-like cells when co-cultured with astrocytes [86, 
134] and BM-derived immature monocytic cells commit 
toward microglia-like cells under similar experimental 
conditions [137]. These microglia-like cells harbor several 
features of native microglia such as a ramified morphology, 
the presence of microspikes and filament-like structures 
detectable by electron microcopy, as well as a characteristic 
pattern of ion channels [73, 134].
By inducing microglia depletion in vivo, rapid repopula-
tion of the brain with new Iba-1-positive cells was obtained 
within 2 week [155]. The engrafted cells expressed high 
levels of CD45 and CCR2 and pattern of expression sug-
gesting they consisted of peripheral monocytes. Although 
two times more numerous, the overall distribution of the 
engrafted cells was remarkably similar to that of micro-
glia. These findings suggest that blood-derived monocytes 
infiltrate and engraft in the microglia-depleted mouse brain 
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regions, having the potential to occupy the adult CNS 
myeloid niche normally inhabited by microglia [155]. 
Myeloid cell engraftment was rapid and appeared limited 
to the period of microglial depletion, but the presence of 
newly engrafted cells remained remarkably stable over 
time (27 weeks) suggesting these cells are long-lived. 
These cells were capable of migrating to and sending pro-
cesses toward acute lesion of neuronal damage, in similar 
fashion as microglia [8, 167] and phenotypic characteri-
zation revealed similarities with resident microglia. These 
findings suggest that, in microglia-depleted adult brain the 
newly engrafted myeloid cells could perform surveillance 
and scavenging functions similar to microglia.
These cells could exert therapeutic effects particularly in 
specific circumstances when selective loss and dysfunction 
of microglia or microglia senescence are observed in dis-
ease processes and in the aged brain. Since resident micro-
glia appear to degenerate during aging-related disorders 
such as Alzheimer’s disease [48, 148], one might consider 
the use of BM myeloid cells or monocytes to compensate 
the defective functions of senescent resident microglia. 
Indeed, in a model of Alzheimer’s disease BMDM were 
shown to be more efficient than resident microglia in elimi-
nating amyloid plaques [143, 145]. A beneficial effect of 
monocytic engraftment in CNS tissue was also demon-
strated in spinal cord injury [140].
Microglia enzyme factory to treat Lysosomal storage 
diseases
Lysosomal storage disorders (LSDs) comprise a heteroge-
neous group of more than 40 inborn errors of metabolism 
caused by mutations in genes encoding soluble lysosomal 
hydrolases, integral membrane proteins and transporters 
and characterized by tissue substrate deposits [1, 107]. Pro-
tein deficiency results in abnormal catabolism of specific 
byproducts and impaired intracellular turnover of a broad 
range of molecules including sphingolipids, glycoproteins 
glycosaminoglycans, and glycogen, leading to the accumu-
lation of these substrates in tissues and organs. This sub-
strate accumulation in lysosomes affects the architecture 
and function of the cells and the tissues. Most lysosomal 
enzymes are ubiquitously expressed and their absence 
causes a broad spectrum of systemic and CNS manifesta-
tions. CNS involvement is observed in up to 70 % of LSD, 
leading to neurodegeneration and/or dysmyelination. The 
severity of the CNS disease ranges from mild mental retar-
dation with minimal alteration of cognitive function to 
severe and rapidly progressing disability and death.
Interestingly, in several LSDs the primary protein defect 
may be further exacerbated in the CNS by microglia acti-
vation that develops as a primary reaction to substrate 
accumulation within these cells and/or an inflammatory 
response to a primary neuronal damage caused by the dis-
ease [150].
Most of therapeutic approaches developed for LSD 
take advantage of the trafficking of lysosomal enzymes 
and a phenomenon referred to as “cross-correction”. Cor-
rect trafficking of lysosomal enzymes requires posttrans-
lational modifications [113]. Newly synthesized enzymes 
are glycosylated in the endoplasmic reticulum and then 
phosphorylated in the Golgi apparatus on the 6 position of 
the terminal mannose residues (M6P) and sorted as inac-
tive proenzymes to the lysosomes. A fraction escapes this 
lysosomal sorting pathway and is secreted in the extracel-
lular space [1]. The secreted proenzyme can be recaptured 
by neighboring or producer cells using the M6P receptor 
expressed on the cellular membrane. Current therapeutic 
approaches take advantage of this secretion/uptake system 
to provide an exogenous supply of the missing enzyme that 
can be taken up by target cells and thus correct the meta-
bolic defect.
A major therapeutic advance for the treatment of LSD 
has been the parenteral injection of recombinant proen-
zyme, a strategy called enzyme replacement therapy for 
those LSD with no involvement of the CNS, like non-neu-
ropathic Gaucher, Fabry, or Pompe diseases [14, 15, 45, 
69]. However, this strategy is non-efficient to correct CNS 
involvement, since the blood–brain barrier limits the access 
of the systemically delivered enzyme to the CNS.
Replacing microglia using HCT to treat LSD
A significant advantage of HCT is that donor-derived, 
enzyme-producing cells are able to migrate to the brain. 
HCT for LSD has been performed for nearly 30 years, with 
the goal to repopulate recipient hematopoietic system with 
cells expressing the functional missing enzyme and stop 
the slow evolution of the disease and prevent the onset of 
clinical symptoms [10, 46, 118, 119, 147]. In that strategy, 
replacing deficient macrophages and microglia by normal 
cells combines the advantage of furnishing the tissues and 
particularly the brain with a critical enzyme source, with 
the potential restoration of scavenger function [43, 64, 81].
The first proof of efficacy of this strategy to stop the 
evolution of LSD was made in Hurler syndrome (MPS 
I). Mucopolysaccharidosis (MPS) are a family of inher-
ited disorders caused by deficiency of lysosomal enzymes 
needed to degrade glycosaminoglycans (GAGs). Since 
the first transplantations performed 30 years ago [107], 
major beneficial results have been obtained in patients with 
Hurler syndrome [79, 147, 150]. From these impressive 
results, it was expected that all MPS could be treated by 
HCT. However, benefit from HCT only appears to be sig-
nificant for MPS vI (Maroteau-Lamy) [80] and vII (Sly) 
[162] although the reasons for this remain unclear. efficacy 
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of HCT differs between the different storage diseases, 
in part because the recruitment of macrophage/micro-
glia, mediated by chemokines that facilitate the migration 
of blood-derived cells to the brain differs in the different 
pathologies [160]. Beside MPS, HCT has beneficial effects 
in pre-symptomatic or late-onset Krabbe disease, and in the 
attenuated forms of metachromatic leukodystrophy [69]. 
Overall, the therapeutic effects of HCT in LSD with CNS 
involvement depends on the severity and on the time course 
of the disease [15]. The best results are obtained when HCT 
is performed at a very early stage of disease progression, or 
even in pre-symptomatic patients early identified because 
of family history. efficacy is strongly dependent on the 
delay between the onset of the symptoms and the transplan-
tation procedure, and limits the indications of allogeneic 
HCT [20, 22]. This underlines the need for defining opti-
mal conditioning to improve microglia renewal from donor 
cells early after transplantation (see above) [27]. Microglia 
is a site of storage and a critical player in disease neuro-
pathology, and could be particularly sensitive to the toxic 
effect of busulfan, as suggested by the higher donor chi-
merism observed in LSD models after HCT [21, 131].
Hematopoietic cell gene therapy to overcome the limits 
of HSC efficacy in LSD
Besides safety (reduced risks associated with allogeneic 
transplantation and particularly graft versus host disease), 
the major advantage of the use of genetically corrected 
autologous compared to allogeneic HCT is the possible 
improvement of the therapeutic potential due to higher 
expression of the missing enzyme compared to the normal 
level (Fig. 2). Preclinical evidence of efficacy was obtained 
in MLD and GLD (globoid leukodystrophy) for which allo-
geneic transplant was shown to be inefficient [115, 122]. 
Based on these results a clinical application was devel-
oped in patients with early forms of MLD leading to very 
encouraging results with enzyme activity restoration at 
above-normal levels in the cerebrospinal fluid and substan-
tial clinical benefit in treated patients [13].
HCT to replace deficient microglia in X-ALD
Long-term follow-up have confirmed that hematopoietic 
cell transplantation (HCT) can arrest the neuroinflamma-
tory demyelinating process of X-ALD when the proce-
dure is performed at an early stage of the disease (mini-
mal neurologic and neuropsychological deficits, limited 
extension of demyelinating lesions at brain MRI [11, 96]. 
However, demyelinating lesions continue to expand after 
transplantation usually for 12–18 months, before this pro-
gression is arrested. This delay in the benefit of HCT is 
likely due to the slow replacement of brain microglia from 
BM-derived cells [30, 72]. experiments in vivo in X-ALD 
mouse showed that transplantation of Sca-1 hematopoietic 
stem cells resulted in the replacement of only 20–25 % of 
brain microglial cells 12 months after transplantation [30]. 
Inflammatory demyelination and microglial cell death 
allow long-term repopulation of the brain parenchyma with 
macrophages/microglia derived from peripheral hemat-
opoietic cell progenitors [27, 165, 166]. The integrity of the 
blood–brain barrier is probably an important issue for HCT 
efficiency in ALD, since most successfully transplanted 
patients had enhanced contrast of cerebral demyelinating 
lesions after intravenous injection of gadolinium reflecting 
abnormal blood–brain barrier. This confirms mice data sug-
gesting the need of blood–brain barrier disruption for mye-
loid progenitors to penetrate into the brain and differentiate 
into microglia-like cells [3, 29, 99, 100].
The mechanism by which allogeneic HCT arrests the 
cerebral demyelinating process and brain inflammation in 
cerebral X-ALD is still incompletely understood. The con-
ditioning regimen has no effect by itself [139]. From the 
series of 36 ALD patients that received allogeneic HCT in 
France, four patients with no or delayed engraftment after 
full myeloablating conditioning regimen with busulfan and 
cyclophosphamide uniformly suffered devastating progres-
sion of cerebral demyelination [29]. In contrast to HCT 
performed for LSD, there is no possible cross-correction of 
other cell types after HCT in X-ALD since ABCD1 peroxi-
somal membrane protein cannot be secreted. This is con-
firmed by HCT experiments in X-ALD mouse. The murine 
model of X-ALD accumulates vLCFAs in all tissues, 
including the brain [123]. HCT in ALD mouse does not 
correct the accumulation of vLCFA in the brain, confirm-
ing the absence of metabolic cross-correction, in contrast to 
CNS lysosomal diseases. However HCT corrects oxidative 
stress damage in the spinal cord (N Cartier and A Pujol, 
unpublished results). Allogeneic transplantation in X-ALD 
probably corrects the abnormal function of brain microglia, 
even it is still unknown if this deficiency is directly related 
to the accumulation of vLCFA.
Hematopoietic cell gene therapy in ALD
Allogeneic HCT remained associated with significant risks 
of severe graft vs. host disease and prolonged immune 
deficiency and a high mortality risk [32, 65]. Transplanta-
tion of autologous HSCs genetically modified to express 
the missing ALD protein may circumvent these severe 
complications (Fig. 2). In vitro experiments of ALD gene 
transfer with lentiviral vectors have shown biochemical 
correction of monocytes/macrophages derived from trans-
duced ALD-deficient human CD34+ cells [17]. In vivo, the 
xenotransplantation of lentivirally transduced human ALD 
CD34+ cells into non-obese diabetic/severe combined 
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immunodeficient (NOD/SCID) mice demonstrated that 
these human genetically modified hematopoietic cells were 
able to migrate into the brain of transplanted mice and to 
differentiate into microglia-like cells expressing the human 
ALD protein [10, 17]. Four X-ALD patients who were can-
didate for allogeneic HCT but had no HLA-matched donor 
have been treated using HSC gene therapy with lentiviral 
vector [30]. The number of hematopoietic cells express-
ing ALD protein reached around 25 % of peripheral blood 
cells from the treated patients 30 days after infusion of the 
transduced CD34+ cells. This percentage decreased with 
time but stabilized between 12 and 16 months to 10–15 %. 
Despite this limited number of corrected hematopoietic 
cells, the results of hematopoietic cell gene therapy in 
Fig. 2  Transplantation of genetically modified hematopoietic stem 
cells to treat CNS diseases. After harvesting hematopoietic cells from 
the bone marrow of the patient, the CD34+ cell fraction containing 
hematopoietic stem cells (HSC) is purified and transduced with a 
lentiviral vector carrying the therapeutic gene. This gene can be the 
normal version of a deficient gene in patients with genetic diseases 
(ABDC1 in X-ALD, MeCP2 in Rett syndrome, lysosomal enzymes) 
or genes coding proteins of therapeutic interest like trophic factors, 
chemokines, and guidance molecules. Transduction with the lenti-
viral vector leads to stable integration of the therapeutic gene in the 
population of stem/progenitor cells. Genetically modified cells are re-
infused into the patient and reconstitute the bone marrow stem cell 
compartment. A fraction of stem cells or myeloid progenitors is able 
to migrate to the CNS, cross the brain barrier and locally differenti-
ate into genetically modified microglia-like cells. Chemokines (cell 
migration/chemotaxis inducing cytokines), such as monocyte che-
moattractant protein 1 CCL2/MCP-1 and fractalkine CX3CL1/Fkn, 
produced by neurons, astrocytes and microglia, appear to attract 
peripheral blood mononuclear cells (PBMC) across the BBB into 
the brain parenchyma. Particularly, monocyte chemoattractant pro-
tein 1 (MCP-1) is and its receptor CCR2 have been implicated in 
a number of inflammatory diseases and are likely to be essential in 
this recruitment of bone marrow-derived cells. Migration of blood 
peripheral blood monocytic cells (PBMC) across the BBB into the 
brain parenchyma also depends on increased expression of various 
adhesion molecules, such as vCAM-1 ICAM-1, IG9 and e-selectin, 
all of which may promote PBMC attachment and transmigration. 
In the case of lysosomal diseases, lentivirus-mediated lysosomal 
enzyme overexpression allows efficient cross-correction of neurons 
and glial cells with diffusion of the therapeutic effect (left). HSC can 
also be engineered to express trophic factors with potential beneficial 
effects on surrounding neurons or glial cells (center). In diseases like 
X-ALD or Rett syndrome, the correction of deficient microglial func-
tion by transplantation of cells genetically modified with lentiviral 
vectors allows mitigation of neuronal damages induced by endog-
enous dysfunctioning microglia (right)
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X-ALD with up to 7 years follow-up are comparable to the 
results of uncomplicated allogeneic transplantation in terms 
of disease outcome, with no side effects particularly no 
genotoxicity [30] (P Aubourg and N Cartier, unpublished 
results). These beneficial results could, in part, be explained 
by the fact that the ALD protein was overexpressed in 
HSCs and myeloid progenitors capable of colonizing the 
CNS. Although there is no evidence of a selective growth 
advantage of corrected microglia-like cells in ALD, their 
precursors might have some advantage in expanding within 
the ALD brain environment. As previously discussed, it is 
also possible that brain microglia cells from treated patients 
might be replaced by infused short-lived progenitors that 
contain a higher proportion of gene-corrected cells.
The fact that only partial correction of the hematopoi-
etic cells is sufficient to stop the progression of the cerebral 
disease is of importance for future therapeutic indications. 
The mortality risk of HCT performed with HLA-matched 
unrelated donor or cord blood remains close to 15–20 % in 
children and 30 % in adults when using full myeloablative 
conditioning regimen commonly used in ALD with cyclo-
phosphamide and busulfan. Reduced intensity conditioning 
(RIC) regimen with a lower risk of toxicity could possibly 
allow to propose HCT to ALD patients at a slightly more 
advanced stage of cerebral demyelination and in adults in 
whom a full myeloablation is associated with significant 
toxicity and mortality risks [29, 114, 127, 154]. However, 
this should be balanced with recent results in mice suggest-
ing that the use of busulfan-based conditioning could favor 
a sustained brain chimerism of the transduced cells, poten-
tially higher than the one detected in the hematopoietic sys-
tem [27].
Conclusion
The fact that microglia play multiple roles in human dis-
ease is well established. Defects in microglia can lead to 
their inability to perform some physiological functions 
such as debris clearance or enhance other functions, such 
as the secretion of neurotoxic factors, to the point in which 
they contribute to the establishment of pathogenesis. Thus 
in a large variety of pathologies microglia are thought to be 
promising targets for therapeutic intervention. Yet, due to 
our growing but still incomplete knowledge of the mecha-
nisms underlying their workings, our success in identify-
ing strategies that modulate microglial function in vivo has 
been limited. The most successful therapeutic approaches 
so far have been those that exploit the ability of BM-derived 
myelomonocytic cells to colonize microglial niches within 
the CNS in a myeloablation/transplantation setting. These 
cells can be engineered to produce disease-modifying fac-
tors, such as specific enzymes missing in lysosomal storage 
diseases, thus serving as long-term drug delivery factories 
for the treatment of neurological diseases, or restore micro-
glia dysfunction, thus serving as real cell therapy. In all 
these applications, microglia replacement can play a criti-
cal role in many CNS diseases that currently lack effica-
cious treatments.
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